Experts discuss how to be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the burdens associated with anemia in CKD, pathophysiological mechanisms involved in CKD-related anemia, and recent outcomes from clinical trials evaluating HIF-PHIs in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.

Earn Credit/ Learning Objectives and Disclosures
https://integrityce.com/ckdanemiapodcast1

Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.